Riskpilot← Back to searchSign inGet full accessBioScienceDirect Europe AB
ABIn liquidationOrg 5591205983Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20171 employees
Revenue 2024
SEK 0
EBITDA margin
—
+1% vs 2023
Equity ratio
75.0%
Financial strength
Net profit 2024
SEK -15K
+4% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -16K | +1% |
| Net profit | SEK -15K | +4% |
| Total assets | SEK 47K | -79% |
| Equity | SEK 35K | -79% |
| Employees | 1 | — |
Legal name
BioScienceDirect Europe AB
Org number
5591205983
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
31 juli 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-06-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn externa firmatecknarna
Company purpose
Bolaget skall bedriva konsult och marknadsföringstjänster av teknisk utrustning inom forskning och vetenskap samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 869 | 232 | 44 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 494 | −119 | −369 | −16 | −16 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | 494 | −119 | −369 | −16 | −16 |
| Net financials | — | −1 | — | — | 0 |
| Profit before tax | 494 | −119 | −369 | −16 | −15 |
| Tax | −106 | −0 | −0 | −0 | — |
| Net profit | 388 | −119 | −369 | −16 | −15 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 299 | 933 | 419 | 219 | 47 |
| Equity | 1 216 | 919 | 366 | 163 | 35 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 83 | 14 | 53 | 56 | 12 |
| Total debt | 83 | 14 | 53 | 56 | 12 |
EBITDA margin
-1585600.0%
This company
15.8%
Market median
-10035543% vs market
20202024
Equity ratio
75.0%
This company
38.2%
Market median
+96% vs market
20202024
Return on equity
-44.1%
This company
18.4%
Market median
-340% vs market
20202024
Net profit margin
-1539300.0%
This company
8.1%
Market median
-19003804% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
MV External Signatory | External Signatory | 2024 |
AB External Signatory | External Signatory | 2024 |
AE Liquidator | Liquidator | 2024 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Board of Directors | 2022 – 2024 | |
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BioScienceDirect Europe AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mona Veronica Vesterberg | External Signatory | 0 companies |
| Anna Birgitta Emanuelsson | External Signatory | 0 companies |
| Anna Elisabeth Adolfsson | Liquidator | 0 companies |
| Peter John Hepburn | Board of Directors | 0 companies |
| Anne Liv Elisabeth Soop | Deputy Board Member | 0 companies |